Angiopoietin-1 gene-modified human mesenchymal stem cells promote angiogenesis and reduce acute pancreatitis in rats

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 3580-3595

  Hua, Jie ^a   He, Zhi Gang ^a   Qian, Dao Hai ^a   Lin, Sheng Ping ^a   Gong, Jian ^a   Meng, Hong Bo ^a   Yang, Ting Song ^a   Sun, Wei ^a   Xu, Bin ^a   Zhou, Bo ^a   Song, Zhen Shun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute pancreatitis; Angiopoietin 1; Gene therapy; Mesenchymal stem cells

Indexed keywords

ANGIOPOIETIN 1; ANGPT1 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PANCREATITIS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANGIOPOIETIN-1; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATITIS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84906236944     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lund H, Tønnesen H, Tønnesen MH and Olsen O. Long-term recurrence and death rates after acute pancreatitis. Scand J Gastroenterol 2006; 41: 234-238.
2. McKay CJ and Imrie CW. The continuing challenge of early mortality in acute pancreatitis. Br J Surg 2004; 91: 1243-1244.
3. Chan YC and Leung PS. Acute pancreatitis: animal models and recent advances in basic research. Pancreas 2007; 34: 1-14.
4. Bhatia M, Wong FL, Cao Y, Lau HY, Huang J, Puneet P and Chevali L. Pathophysiology of acute pancreatitis. Pancreatology 2005; 5: 132-144.
5. Frossard JL, Steer ML and Pastor CM. Acute pancreatitis. Lancet 2008; 371: 143-152.
6. Ishibashi T, Zhao H, Kawabe K, Oono T, Egashira K, Suzuki K, Nawata H, Takayanagi R and Ito T. Blocking of monocyte chemoattractant protein-1 (MCP-1) activity attenuates the severity of acute pancreatitis in rats. J Gastroenterol 2008; 43: 79-85.
7. Huang L, Ma J, Tang Y, Chen P, Zhang S, Zhang Y and Yuan YZ. siRNA-based targeting of fractalkine overexpression suppresses inflammation development in a severe acute pancreatitis rat model. Int J Mol Med 2012; 30: 514-520.
8. Huang LY, Chen P, Xu LX, Zhou YF, Zhang YP and Yuan YZ. Fractalkine upregulates inflammation through CX3CR1 and the Jak-Stat pathway in severe acute pancreatitis rat model. Inflammation 2012; 35: 1023-1030.
9. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP and Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000; 190: 117-125.
10. Bhatia M. Novel therapeutic targets for acute pancreatitis and associated multiple organ dysfunction syndrome. Curr Drug Targets Inflamm Allergy 2002; 1: 343-351.
11. Friedenstein AJ, Piatetzky-Shapiro II and Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966; 16: 381-390.
12. Caplan AI and Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011; 9: 11-15.
13. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P and Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
14. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K and Phinney DG. Interleukin1receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007; 104: 11002-11007.
15. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K and Ozawa K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234.
16. Xu J, Qu J, Cao L, Sai Y, Chen C, He L and Yu L. Mesenchymal stem cell-based angiopoietin-1gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 2008; 214: 472-481.
17. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG and Kong D. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16: 571-579.
18. Wu J, Sun Z, Sun HS, Wu J, Weisel RD, Keating A, Li ZH, Feng ZP and Li RK. Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischemic rats. Cell Transplant 2008; 16: 993-1005.
19. Lai VK, Afzal MR, Ashraf M, Jiang S and Haider HKh. Non-hypoxic stabilization of HIF-Ia during coordinated interaction between Akt and angiopoietin-1 enhances endothelial commitment of bone marrow stem cells. J Mol Med (Berl) 2012; 90: 719-730.
20. Kwak HJ, So JN, Lee SJ, Kim I and Koh GY. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 1999; 448: 249-253.
21. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G and Vadas MA. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000; 87: 603-607.
22. Thurston G, Rudge JS, Ioffe E, Papadopoulos N, Daly C, Vuthoori S, Daly T, Wiegand SJ and Yancopoulos GD. The anti-inflammatory actions of angiopoietin-1. EXS 2005; 94: 233-245.
23. Piao W, Wang H, Inoue M, Hasegawa M, Hamada H and Huang J. Transplantation of Sendai viral angiopoietin-1-modified mesenchymal stem cells for ischemic limb disease. Angiogenesis 2010; 13: 203-210.
24. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC and Sessa WC. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000; 275: 9102-9105.
25. Sun L, Cui M, Wang Z, Feng X, Mao J, Chen P, Kangtao M, Chen F and Zhou C. Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction. Biochem Biophys Res Commun 2007; 357: 779-784.
26. Toyama K, Honmou O, Harada K, Suzuki J, Houkin K, Hamada H and Kocsis JD. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp Neurol 2009; 216: 47-55.
27. Weir C, Morel-Kopp MC, Gill A, Tinworth K, Ladd L, Hunyor SN and Ward C. Mesenchymal stem cells: isolation, characterisation and in vivo fluorescent dye tracking. Heart Lung Circ 2008; 17: 395-403.
28. Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, Sano T, Kosuge T, Nimura Y, Kanai Y and Hiraoka N. Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 2007; 13: 187-196.
29. Kiem HP, Jerome KR, Deeks SG and McCune JM. Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 2012; 10: 137-147.
30. Losordo DW and Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 2004; 109: 2692-2697.
31. Goldman S. Stem and progenitor cell-based therapy of the human central nervous system. Nat Biotechnol 2005; 23: 862-871.
32. Bao Q, Zhao Y, Niess H, Conrad C, Schwarz B, Jauch KW, Huss R, Nelson PJ and Bruns CJ. Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Stem Cells Dev 2012; 21: 2355-2363.
33. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC and Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin1. PLoS Med 2007; 4: 1525-1537.
34. von Dobschuetz E, Pahernik S, Hoffmann T, Kiefmann R, Heckel K, Messmer K, Mueller-Hoecker J and Dellian M. Dynamic intravital fluorescence microscopy-a novel method for the assessment of microvascular permeability in acute pancreatitis. Microvasc Res 2004; 67: 55-63.
35. Aggarwal S and Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
36. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC and Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150.
37. Meng HB, Gong J, Zhou B, Hua J, Yao L and Song ZS. Therapeutic effect of human umbilical cord-derived mesenchymal stem cells in rat severe acute pancreatitis. Int J Clin Exp Pathol 2013; 6: 2703-2712.
38. Jung KH, Song SU, Yi T, Jeon MS, Hong SW, Zheng HM, Lee HS, Choi MJ, Lee DH and Hong SS. Human bone marrow-derived clonal mesenchymal stem cells inhibit inflammation and reduce acute pancreatitis in rats. Gastroenterology 2011; 140: 998-1008.
39. Edwards SS, Zavala G, Prieto CP, Elliott M, Martínez S, Egaña JT, Bono MR and Palma V. Functional analysis reveals angiogenic potential of human mesenchymal stem cells from Wharton's jelly in dermal regeneration. Angiogenesis 2014; [Epub ahead of print].
40. Huang LY, Chen P, Xu LX, Zhou YF, Li WG and Yuan YZ. Fractalkine as a marker for assessment of severe acute pancreatitis. J Dig Dis 2012; 13: 225-231.
41. Uomo G, Gallucci F, Madrid E, Miraglia S, Manes G and Rabitti PG. Pancreatic functional impairment following acute necrotizing pancreatitis: long-term outcome of a non-surgically treated series. Dig Liver Dis 2010; 42: 149-152.